Browse the evidence

Changes in specific health behaviors (physical activity, diet composition, alcohol, smoking) were not consistently associated with diabetes remission in this study.

While weight loss is crucial, simply trying to change your diet or exercise habits without focusing on the resulting weight loss may not be enough to put diabetes into remission. The weight loss itself is the key factor.

High body mass index (BMI) is a strong independent risk factor for the development and progression of Chronic Kidney Disease (CKD), primarily driven by compensatory glomerular hyperfiltration and increased intraglomerular pressure.

Maintaining a healthy weight is one of the most effective ways to protect your kidneys. Excess body weight forces your kidneys to work harder (hyperfiltration), which can cause long-term damage. While weight loss is complex in advanced kidney disease, preventing obesity is a primary strategy for avoiding kidney failure.

Semaglutide 2.4 mg once weekly does not increase the risk of developing symptoms of depression or suicidal ideation/behavior compared to placebo in people with overweight or obesity without known major psychopathology.

If you are considering semaglutide for weight loss and are worried about your mental health, know that large clinical trials show it does not increase the risk of depression or suicidal thoughts compared to a placebo. While you should still monitor your mood as recommended, the medication itself is not causing these psychiatric issues. This is particularly reassuring if you have no history of major mental health conditions.

Obesity directly causes chronic kidney disease (CKD) and end-stage renal disease (ESRD) through compensatory hyperfiltration, glomerular hypertension, and adipose-derived inflammatory mediators, independent of diabetes and hypertension.

Maintaining a healthy body weight is critical for kidney health. Obesity increases pressure inside the kidney's filtering units (glomeruli) and releases hormones that cause inflammation and scarring, leading to chronic kidney disease. This risk exists even if you do not have diabetes or high blood pressure. Preventing obesity through lifestyle changes is the most effective way to protect your kidneys.

Exercise combined with calorie restriction does not induce browning (brite cell formation) in human subcutaneous white adipose tissue; instead, it is associated with decreased UCP1 expression, suggesting a 'whitening' or adaptive response to energy deficit rather than increased thermogenesis.

If you are losing weight through exercise and diet, do not expect your fat cells to turn into 'brown fat' that burns extra calories. Your body actually adapts by reducing the expression of thermogenic proteins (like UCP1) in your white fat, likely to conserve energy during a deficit. This is a normal, adaptive response to weight loss, not a failure of your exercise program. The weight loss is driven by the calorie deficit, not by creating new heat-generating fat cells.

Replacing saturated fatty acids (SFAs) with carbohydrates does not significantly alter coronary heart disease (CHD) incidence, indicating that the specific macronutrient substitution of SFA for carbohydrate is not a primary driver of CHD risk in isolation.

Do not assume that simply swapping saturated fats for carbohydrates will lower your risk of heart disease. This study suggests that the macronutrient swap itself has no significant effect on CHD incidence. Instead, focus on the quality and source of the foods you eat.

GLP-1 RAs can cause clinically significant drug-drug interactions (DDIs) by delaying gastric emptying, particularly affecting the absorption of oral contraceptives and levothyroxine.

If you take oral contraceptives or levothyroxine, be aware that GLP-1 drugs can change how well these work by slowing stomach emptying. Your doctor may need to monitor your levels or adjust doses. Use backup contraception if advised.

Initiation of modern antiretroviral therapy (ART), specifically integrase strand transfer inhibitors (INSTIs) like dolutegravir and bictegravir combined with tenofovir alafenamide (TAF), causes significant, sustained weight gain in people living with HIV, disproportionately affecting women and Black patients.

If you are living with HIV and starting or taking modern medication (specifically drugs ending in '-gravir' like dolutegravir or bictegravir, and TAF), expect significant weight gain, especially if you are a woman or Black. This is not just 'getting older' or 'eating too much'; it is a known side effect of the medication's interaction with your metabolism. Talk to your doctor about your risk factors. They may consider regimens with TDF (which mitigates weight gain) or other alternatives, though these may have other side effects. Be aware that standard diet and exercise might be less effective for this specific type of gain, and emerging weight-loss medications might be considered in the future.

Integrase strand transfer inhibitors (INSTIs), particularly dolutegravir and bictegravir, are the primary drivers of weight gain in modern ART regimens, with effects observed as early as 4 weeks post-initiation.

If you are taking an INSTI (like dolutegravir or bictegravir), be aware that these drugs are strongly linked to weight gain, often starting within weeks of taking them. This is a known side effect of the drug class, not just your lifestyle. If you are at high risk (e.g., woman, Black patient), discuss your concerns with your doctor. They might consider alternative regimens, though these may have other trade-offs.

Caffeine does not significantly enhance upper-body muscle endurance (bench press repetitions) at any tested dose (2, 4, or 6 mg/kg).

If you are doing single-set upper-body endurance tests (like bench press to failure at 60% 1RM), caffeine is unlikely to help you perform more repetitions, regardless of the dose. This contrasts with lower-body endurance, where caffeine is effective.

When subcutaneous white adipose tissue (scWAT) reaches its maximal storage capacity, it becomes dysfunctional and fails to store lipids appropriately, leading to ectopic fat accumulation in the liver and visceral depots, thereby causing non-alcoholic fatty liver disease (NAFLD).

If you are obese, your body's ability to store fat safely in your subcutaneous areas (like thighs and arms) may be maxed out. Once this 'buffer' is full, excess fat spills over into your liver and visceral organs, causing disease. Strategies to improve metabolic health should focus on preventing this overflow, potentially through interventions that support adipose tissue health or reduce caloric intake to match storage capacity.

Biomarker-based personalized nutrition plans do not result in greater weight loss or improvements in cardiometabolic health compared to a generic, generally healthy diet in individuals with overweight or obesity.

If you have overweight or obesity, following a generally healthy, balanced diet that provides enough food to satisfy you will result in similar weight loss and health improvements as following a highly personalized, biomarker-driven diet plan. You do not need to undergo expensive metabolic testing or follow complex personalized rules to achieve significant health benefits; consistency with a healthy, isocaloric diet is sufficient.

GLP-1 monotherapy (liraglutide, semaglutide) is associated with high discontinuation rates due to gastrointestinal side effects, limiting long-term adherence.

Be aware that GLP-1 monotherapy can cause significant gastrointestinal side effects, leading to high discontinuation rates. Discuss titration strategies with your provider to minimize these effects.

GLP-1 receptor activation suppresses glucagon secretion primarily through an indirect mechanism involving somatostatin release from delta-cells, rather than direct action on alpha-cells.

GLP-1 drugs help control blood sugar not just by boosting insulin, but by suppressing glucagon (a hormone that raises blood sugar). This suppression happens indirectly by stimulating other cells (delta-cells) to release somatostatin, which then inhibits glucagon. This dual action makes GLP-1 drugs effective for lowering blood glucose.

Ghrelin, the 'hunger hormone', directly stimulates reward pathways in the brain (VTA and NAc) to increase motivation and willingness to work for food, particularly palatable/high-fat foods.

Hunger isn't just an empty stomach; it's a biological signal that boosts your brain's reward system for food. This is why cravings feel so compelling. Understanding this biological drive can help separate the feeling of hunger from the act of eating.

Bariatric surgery is associated with a higher rate of adverse events compared to non-surgical treatment, although early complications are often benign and long-term complications may be fewer in surgical groups.

Bariatric surgery is associated with a higher rate of adverse events compared to medical management, but these are often early and benign. Long-term, surgery may reduce the risk of serious diabetes-related complications. Patients should weigh the higher short-term risk of surgery against the potential long-term benefits of reduced complications and improved metabolic health.

GLP-1 receptor agonists directly modulate immune cell function, specifically suppressing T-cell activity and pro-inflammatory cytokine release, independent of metabolic changes.

GLP-1 medicines interact directly with your immune system. They can dampen the activity of T cells, which are key drivers of inflammation. This direct interaction helps reduce the production of inflammatory markers like TNF-α and IL-2, contributing to overall health benefits beyond blood sugar control.

GLP-1 receptor agonists reduce cardiovascular events and atherosclerosis progression through weight-loss-independent anti-inflammatory mechanisms involving endothelial and immune cell modulation.

GLP-1 medications like semaglutide and liraglutide are proven to reduce the risk of heart attacks, strokes, and cardiovascular death in people with type 2 diabetes and obesity. This protection is partly due to direct anti-inflammatory effects on blood vessels, independent of weight loss. These benefits are significant enough to be a primary reason for prescribing these drugs in high-risk patients.

Aerobic fitness level (VO2 max) does not independently increase daily energy expenditure in weight-stable humans; its apparent association with higher energy expenditure is entirely mediated by its positive correlation with fat-free mass (FFM).

If you are weight-stable, your daily calorie expenditure is driven almost entirely by your fat-free mass (muscle and organ mass), not by your aerobic fitness level (VO2 max). While exercise improves fitness, it does not independently boost your resting or total energy expenditure beyond the metabolic cost of the activity itself and any muscle gained. To increase your baseline energy expenditure, focus on preserving or building fat-free mass rather than assuming high cardio fitness alone will significantly raise your daily burn.

Higher habitual dairy intake does NOT causally affect glycemic traits (fasting glucose, insulin, HbA1c) in adults, despite observational associations.

You do not need to avoid dairy for blood sugar control. The study suggests dairy does not causally affect glycemic traits, so it can be included in a healthy diet without fear of worsening blood sugar levels.

Chronic inflammation, oxidative stress, and gut dysbiosis form a reciprocal triad that perpetuates the pathophysiology of obesity.

Focus on reducing inflammation through diet (anti-inflammatory foods, fiber) and managing stress, as these factors directly impact gut health and oxidative stress, which in turn affect weight regulation.

Reduction of adipocyte-derived SPARC protects against high-fat diet-induced obesity and metabolic dysfunction in female mice by enhancing energy expenditure and lipolysis.

This research identifies SPARC, a protein elevated in obesity, as a key regulator of fat storage. Reducing SPARC (naturally via caloric restriction or potentially via future therapies) may help manage weight by increasing energy expenditure and breaking down fat, particularly in women. While not a direct diet advice, it highlights that lowering this specific protein is linked to improved metabolic health.

SPARC acts as a priming signal for the NLRP3 inflammasome in macrophages, driving chronic inflammation associated with obesity.

Chronic inflammation in obesity is driven by SPARC activating immune cells. Reducing SPARC levels, as seen with weight loss, reduces this inflammation.

GLP1R agonism reduces coronary artery disease (CAD) risk primarily through body weight lowering (BMI) rather than through the reduction of type 2 diabetes (T2D) liability.

If you are using a GLP-1 agonist (like semaglutide or tirzepatide) for heart health, the primary benefit comes from the weight loss it induces, not just from lowering blood sugar. Even if your blood sugar is already well-controlled, the drug's effect on reducing body weight is what significantly lowers your risk of coronary artery disease. This supports using these medications for cardiovascular prevention in obese individuals, regardless of diabetic status.